| Literature DB >> 31205702 |
Btissame Zouini1, Anis Sfendla1, Meftaha Senhaji1, Maria Råstam2, Nóra Kerekes3.
Abstract
BACKGROUND: Adolescence is a distinct developmental phase characterized by multiple physical and psychological changes and by an increased vulnerability to somatic and mental health problems. These risk and vulnerability factors are part of a complex biopsychosocial matrix, encompassing multiple factors, such as inherited biological determinants and psychological, societal, and cultural influences, which affect an adolescent's overall wellbeing. In Morocco, similar to other developing countries, adolescents (young people aged from 15 to 19 years) constitute a substantial proportion of the population (almost 9%). However, studies about adolescents' health in developing countries are scarce. In this study, we describe adolescents' somatic health in a sample of high school students from the city of Tetouan, Morocco, and investigate how negative psychosocial factors, such as parental alcohol use problems and/or the experience of abuse, may influence them.Entities:
Keywords: Morocco; adolescents; parental alcohol use problems; physical or psychological abuse; somatic health
Year: 2019 PMID: 31205702 PMCID: PMC6535729 DOI: 10.1177/2050312119852527
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Test–retest reliability of the MeSHe background questionnaire assessed in a class of high school students (N = 31) with a 2-week interval.
| Time 1 (yes/no)[ | Time 2 (yes/no)[ | Chi-square test | |||
|---|---|---|---|---|---|
|
| Cramer’s | ||||
| Headaches | (14/13) | (10/20) | 0.65 | 0.34 | 0.16 |
| Diarrhea/constipation | (5/24) | (5/23) | 1.13 | 0.40 | 0.21 |
| Allergy | (5/25) | (4/25) | 0.56 | 0.60 | 0.14 |
| Skin disease | (8/23) | (5/26) | 0.63 | 0.38 | 0.14 |
| Migraine | (3/28) | (2/29) | 0.23 | 0.81 | 0.09 |
| Asthma | (2/29) | (2/29) | 0.15 | 0.88 | 0.07 |
| Epilepsy | (1/30) | (1/29) | 0.04 | 0.97 | 0.03 |
| Gluten intolerance | (1/29) | (0/29) | No statistics computed | ||
| Diabetes | (0/29) | (0/29) | No statistics computed | ||
| Cancer | (0/31) | (0/31) | No statistics computed | ||
| Tuberculosis | (0/31) | (0/31) | No statistics computed | ||
| Thyroid disease | (0/31) | (0/31) | No statistics computed | ||
MeSHe: Mental and Somatic Health without borders.
n includes those answering yes or no to the question.
Prevalence of defined somatic symptoms and diseases in a sample of Moroccan adolescents (N = 655).
| Total sample (yes/no)[ | Boys (yes/no)[ | Girls (yes/no)[ | Chi-square test | |||
|---|---|---|---|---|---|---|
|
| Cramer’s | |||||
| Headaches | (335/248) | (146/136) | (189/112) | 12.6 | 0.002 | 0.14 |
| Diarrhea/constipation | (166/382) | (61/209) | (105/173) | 15.12 | 0.001 | 0.15 |
| Allergy | (138/423) | (53/221) | (85/202) | 7.67 | 0.020 | 0.11 |
| Skin disease | (107/492) | (47/246) | (60/246) | 1.52 | 0.46 | 0.05 |
| Migraine | (85/503) | (44/243) | (41/260) | 2.4 | 0.30 | 0.06 |
| Gluten intolerance | (41/547) | (15/272) | (26/375) | 5.12 | 0.08 | 0.09 |
| Asthma | (33/557) | (12/278) | (21/279) | 2.36 | 0.31 | 0.06 |
| Thyroid disease | (26/580) | (7/287) | (19/293) | 5.09 | 0.08 | 0.09 |
| Epilepsy | (18/570) | (11/271) | (7/299) | 4.36 | 0.11 | 0.08 |
| Diabetes | (11/580) | (6/283) | (5/297) | 0.34 | 0.84 | 0.02 |
| Cancer | (8/609) | (5/302) | (3/307) | 1.46 | 0.48 | 0.05 |
| Tuberculosis | (7/602) | (2/295) | (5/307) | 3.76 | 0.15 | 0.08 |
| None of the above | (187/449) | 108/203 | 79/246 | 8.31 | 0.004 | 0.11 |
n includes those answering yes or no to the question.
Prevalence and risk ratio (RR) of defined somatic symptoms and diseases according to psychosocial variable groups.
| CG ( | PAP ( | PPA ( | Chi-square test | |||||
|---|---|---|---|---|---|---|---|---|
| % | % | RR | % | RR |
| Cramer’s | ||
| Headaches | 49.20 | 67.80 | 1.38 | 75.30 | 1.53 | 23.72 | <0.001 | 0.21 |
| Diarrhea/constipation | 24.50 | 30.20 | 1.23 | 39.80 | 1.56 | 8.00 | 0.020 | 0.13 |
| Allergy | 24.50 | 15.30 | 0.62 | 34.50 | 1.41 | 7.17 | 0.030 | 0.12 |
| Skin disease | 16.10 | 12.10 | 0.75 | 28.60 | 1.78 | 9.28 | 0.010 | 0.13 |
| Migraine | 6.80 | 12.30 | 1.81 | 34.70 | 5.10 | 54.16 | <0.001 | 0.32 |
| Gluten intolerance | 4.30 | 1.70 | 0.39 | 20.00 | 4.65 | 32.30 | <0.001 | 0.25 |
| Asthma | 4.70 | 7.10 | 1.51 | 8.70 | 1.85 | 2.53 | 0.28 | 0.07 |
| Thyroid disease | 1.80 | 1.70 | 0.94 | 14.60 | 8.11 | 33.74 | <0.001 | 0.25 |
| Epilepsy | 1.60 | 1.80 | 1.12 | 8.30 | 5.19 | 12.83 | <0.001 | 0.16 |
| Diabetes | 1.10 | 1.80 | 1.64 | 3.10 | 2.82 | 2.23 | 0.33 | 0.06 |
| Cancer | 1.00 | 0.00 | 0.00 | 3.10 | 1.78 | 3.49 | 0.17 | 0.08 |
| Tuberculosis | 1.80 | 0.00 | 0.00 | 0.00 | 0.00 | 2.80 | 0.25 | 0.07 |
CG: comparison group; PAP: adolescents reporting parental alcohol use problems; PPA: adolescents reporting the experience of physical and/or psychological abuse.
Post hoc analyses for prevalence of defined somatic symptoms and diseases according to psychosocial variable groups.
| CG ( | PAP ( | PPA ( | ||
|---|---|---|---|---|
| Headaches | Adjusted | −4.79 | 1.98 | 4.07 |
|
| 22.94 | 3.92 | 16.56 | |
| <0.001 | 0.14 | <0.001 | ||
| Diarrhea/constipation | Adjusted | −2.55 | 0.43 | 2.69 |
|
| 6.50 | 0.18 | 7.24 | |
| 0.04 | 0.91 | 0.03 | ||
| Allergy | Adjusted | −0.52 | −1.86 | 2.21 |
|
| 0.27 | 3.46 | 4.88 | |
| 0.87 | 0.18 | 0.09 | ||
| Skin disease | Adjusted | −1.64 | −1.21 | 2.95 |
|
| 2.69 | 1.46 | 8.70 | |
| 0.26 | 0.48 | 0.013 | ||
| Migraine | Adjusted | −6.17 | −0.02 | 7.30 |
|
| 38.07 | 0.0004 | 53.29 | |
| <0.001 | 1.00 | <0.001 | ||
| Gluten intolerance | Adjusted | −3.65 | −1.63 | 5.64 |
|
| 13.22 | 2.66 | 31.81 | |
| 0.001 | 0.26 | <0.001 | ||
| Asthma | Adjusted | −1.54 | 0.52 | 1.40 |
|
| 2.37 | 0.27 | 1.96 | |
| 0.31 | 0.87 | 0.37 | ||
| Thyroid disease | Adjusted | −4.24 | −0.96 | 5.81 |
|
| 17.98 | 0.92 | 33.76 | |
| <0.001 | 0.63 | <0.001 | ||
| Epilepsy | Adjusted | −2.69 | −0.52 | 3.58 |
|
| 7.24 | 0.27 | 12.82 | |
| 0.03 | 0.87 | 0.002 | ||
| Diabetes | Adjusted | −1.34 | 0.18 | 1.43 |
|
| 1.79 | 0.03 | 2.04 | |
| 0.40 | 0.98 | 0.36 | ||
| Cancer | Adjusted | −0.82 | −0.94 | 1.75 |
|
| 0.67 | 0.88 | 3.06 | |
| 0.71 | 0.64 | 0.21 | ||
| Tuberculosis | Adjusted | 1.67 | −0.92 | −1.23 |
|
| 2.79 | 0.85 | 1.51 | |
| 0.25 | 0.65 | 0.47 |
CG: comparison group; PAP: adolescents reporting parental alcohol use problems; PPA: adolescents reporting the experience of physical and/or psychological abuse.
Significance level set at p < 0.017 after Bonferroni adjustment.